Sufra health X BioticsAI

​Final Opportunity to Join BioticsAI Before Valuation Increase

​

​Sufra Health x BioticsAI Investor Spotlight and FDA Update Session

​BioticsAI, the recent winner of TechCrunch Disrupt and a category leader in AI-powered prenatal care, has achieved a pivotal regulatory milestone. The FDA has formally accepted their clinical study data, with only minor items remaining ahead of clearance.

​This milestone removes the final gating item before the company’s next valuation step. With momentum accelerating, BioticsAI is now closing its current round and transitioning to the next pricing tier.

​The current $30M valuation cap closes Tuesday, November 4.

​Following this date, new capital will enter at a $60M valuation as the team moves toward its next round.

​This session provides a final opportunity for qualified angels and healthcare operators in the Sufra ecosystem to meet the founding team, review the latest regulatory progress, and understand the investment thesis before terms change.